Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224893 · ClinicalTrials.gov registry record · Phase 4
Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management
A Phase 4 study, sponsored by Eastern Virginia Medical School.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07224893: Recruiting Phase 4 study, sponsored by Eastern Virginia Medical School.
NCT07224893 is a Phase 4 study that is actively recruiting participants, run by Eastern Virginia Medical School. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224893, a Phase 4 study, is actively recruiting participants, sponsored by Eastern Virginia Medical School.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a group that takes it twice. Continuous glucose monitoring will be used to track blood sugar levels. The main question the study aims to answer is: Will using insulin glargine twice a day instead of once lead to a better glucose time in range?
Primary Outcome
The mean blood glucose time in range as measured by the continuous glucose monitor
Interventions
- DRUG Use of insulin glargine once daily
- DRUG Use of insulin glargine twice daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05-18 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 4 |
What NCT07224893 shows while recruiting
NCT07224893 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 2 interventions - of which Use of insulin glargine once daily is the first listed.
NCT07224893 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07224893 about?
NCT07224893 is a clinical study titled "Once-Daily vs Twice-Daily Insulin Glargine in Pregestational Diabetes Management". The purpose of this study is to determine if taking insulin glargine twice a day instead of once a day will better manage pregestational diabetes in pregnant patients. Participants in this study will be randomly assigned to one of two groups: a group that takes insulin glargine once a day, and a gro...
What is the current status of trial NCT07224893?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-05-18. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07224893?
The interventions under investigation include: Use of insulin glargine once daily (DRUG), Use of insulin glargine twice daily (DRUG).
Who is sponsoring clinical trial NCT07224893?
This trial is sponsored by Eastern Virginia Medical School, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07224893's enrollment target sits among peer trials
200 407th of 2000 higher than 1,556 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI